Dr. Silberzweig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 E 70th St
2nd Floor
New York, NY 10021Phone+1 212-746-1562Fax+1 212-746-8439
Summary
- Dr. Jeffrey Silberzweig is a nephrologist in New York, NY and is affiliated with multiple hospitals in the area, including NewYork-Presbyterian/Weill Cornell and NewYork-Presbyterian/Lower Manhattan Hospital. He received his medical degree from University at Buffalo, School of Medicine and Biomedical Sciences and has been in practice 28 years. He is currently the Chief Medical Officer of The Rogosin Institute and has extensive experience in general nephrology and dialysis.
Education & Training
University of Pennsylvania Health SystemFellowship, Nephrology, 1992 - 1994
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1989 - 1992
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1989
Certifications & Licensure
NY State Medical License 1991 - 2026
FL State Medical License 2012 - 2019
PA State Medical License 1991 - 1996- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
Clinical Trials
- Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis Start of enrollment: 2015 Oct 01
- Procalcitonin and Brain Natriuretic Peptides in Patients With Chronic Kidney Disease. Start of enrollment: 2018 Dec 26
- Expanding and Promoting Alternative Care and kNowledge in Decision-making Trial Start of enrollment: 2024 Sep 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 4 citationsA protocol for a pilot randomized controlled trial to assess the feasibility and effect of a cognitive behavioral intervention on quality of life for patients on hemod...Shayan Shirazian, Arlene Smaldone, Maya K. Rao, Jeffrey Silberzweig, Alan M. Jacobson
Contemporary Clinical Trials. 2018-08-29 - 4 citationsRenal Considerations in COVID-19: Biology, Pathology, and Pathophysiology.Meghan E. Kapp, Agnes B. Fogo, Candice Roufouse, Behzad Najafian, Jai Radhakrishnan
ASAIO Journal. 2021-10-01 - 5 citationsChanges in Bone Quality after Treatment with Etelcalcetide.Pascale Khairallah, Jenna Cherasard, Joshua Sung, Sanchita Agarwal, Maria Alejandra Aponte
Clinical Journal of the American Society of Nephrology. 2023-11-01
Press Mentions
Regular SARS-CoV-2 Testing in Hemodialysis Facilities Unacceptable to Most PatientsOctober 1st, 2024- Q&A: Nephrologists Offer Next Steps in Addressing the COVID-19 Omicron VariantDecember 27th, 2021
- Fauci, ASN Panelists Encourage Patients with CKD to Get COVID-19 Booster VaccineNovember 4th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
